BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GSK5460025 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of GSK5460025\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07213609-11216@assetmemo.bio
DTSTAMP:20261121T005740Z
DTSTART;VALUE=DATE:20280928
DTEND;VALUE=DATE:20280929
SUMMARY:GSK5460025: Phase 1/2 readout est. (NCT07213609)
DESCRIPTION:GSK5460025\, phase 1/2.\nStudy: A Study to Investigate the Safe
 ty and Preliminary Efficacy of GSK5460025 Alone or in Combination With Oth
 er Anti-cancer Agents in Participants With Solid Tumors\nEstimated primary
  completion: 28 September 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/gsk5460025#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07213609
URL:https://assetmemo.bio/drug/gsk5460025#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
